Statins, Venous Thromboembolism and Cardiovascular Events

Paraskevi      Tsiantoula; Vasileios      Papaioannou; Nikolaos-Nektarios      Giannakopoulos; Theofanis   T.   Papas

doi:10.2174/0115701611335138240731112405

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Rights & Permissions Print Cite

Current Vascular Pharmacology

Title:Statins, Venous Thromboembolism and Cardiovascular Events

Volume: 22

Author(s): Paraskevi Tsiantoula*, Vasileios Papaioannou, Nikolaos-Nektarios Giannakopoulos and Theofanis T. Papas

Affiliation:

Department of Vascular Surgery, Korgialenio-Benakeio Hellenic Red Cross Hospital, Athens, Greece

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Tsiantoula Paraskevi*, Papaioannou Vasileios, Giannakopoulos Nikolaos-Nektarios and Papas T. Theofanis, Statins, Venous Thromboembolism and Cardiovascular Events, Current Vascular Pharmacology 2024; 22 () . https://dx.doi.org/10.2174/0115701611335138240731112405

DOI https://dx.doi.org/10.2174/0115701611335138240731112405	Print ISSN 1570-1611
Publisher Name Bentham Science Publisher	Online ISSN 1875-6212

About this journal

Call for Papers in Thematic Issues

Submission closes on : 31 January, 2025

TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE

Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

Guest Editor(s): Stefanos Roumeliotis